{"prompt": "['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'IUD', 'Intrauterine device', 'IUS', 'Intrauterine hormone releasing system', 'IVIVT', 'In vitro In vivo Translation', 'IWRS', 'Interactive Web Response System', 'kg', 'Kilogram', 'L', 'Liter', 'LABA', 'Long acting \u00df2 receptor agonist', 'LAMA', 'Long acting muscarinic receptor antagonist', 'LH', 'Leutinizing Hormone', 'MCV', 'Mean corpuscular volume', 'MCH', 'Mean corpuscular hemoglobin', 'MCHC', 'Mean corpuscular hemoglobin count', 'MDI', 'Metered dose inhaler', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'mg', 'Milligrams', 'mL', 'Milliliter', 'MM', 'Medical monitor', 'MSDS', 'Material Safety Data Sheet', 'msec', 'Millisecond', 'NOAEL', 'No observed adverse effect level', 'O2', 'Oxygen', 'PK', 'Pharmacokinetics', 'PR interval; duration in milliseconds from the', 'PR', 'beginning of the P wave to onset of ventricular', 'depolarization (R)', 'PRO', 'Patient Reported Outcome', 'PTS', 'Platform Technology and Science', 'QRS interval; duration in milliseconds of the QRS', 'QRS', 'complex', 'QT interval; duraction in milliseconds between the', 'QT', 'start of the Q wave and the end of the T wave', 'QTcF', 'QT interval corrected for heart rate (Friderica', 'formula)', 'RAP', 'Reporting and Analysis Plan', 'RBC', 'Red blood cells', 'RNA', 'Ribonucleic acid', 'SABA', 'Short-acting \u00df2 Receptor Agonist', 'SAE', 'Serious Adverse Event', '57']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'SAMA', 'Short-acting Muscarinic Receptor Agonist', 'SGRQ', \"St George's Respiratory Questionnaire\", 'SGRQ-C', 'SGRQ-C for COPD patients', 'SRM', 'Study Reference Manual', 'SRT', 'Safety Review Team', 'SOA', 'Schedule of Activities', 'SUSAR', 'Suspected unexpected serious adverse reaction', 't\u00b9/2', 'Terminal phase half-life', 'tmax', 'Time to reach Cmax', 'TPR', 'Third Party Resourcing', 'ULN', 'Upper limit of normal', 'g', 'Microgram', 'VT', 'Ventricular tachycardia', 'WBC', 'White blood cells', 'WOCBP', 'Women of child bearing potential', 'Trademark Information', 'Trademarks of the GlaxoSmithKline', 'Trademarks not owned by the', 'group of companies', 'GlaxoSmithKline group of companies', 'CAT', 'Combivent', 'Duoneb', '58']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.2.', 'Appendix 2: Clinical Laboratory Tests', 'The tests detailed in Table 5 (Protocol-Required Safety Laboratory', 'Assessments) will be performed by the central laboratory, except as noted.', 'Local laboratory results are only required in the event that the central laboratory', 'results are not available in time for either study treatment administration and/or', 'response evaluation. If a local sample is required, it is important that the sample', 'for central analysis is obtained at the same time. Additionally, if the local', 'laboratory results are used to make either a study treatment decision or response', 'evaluation, the results must be entered into the CRF.', 'Protocol-specific requirements for inclusion or exclusion of participants are', 'detailed in Section 6.', 'Additional tests may be performed at any time during the study as determined', 'necessary by the investigator or required by local regulations.', 'Table 5', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Platelet Count', 'RBC Indices:', 'WBC count with', 'RBC Count', 'MCV', 'Differential:', 'Hemoglobin', 'MCH', 'Neutrophils', 'Hematocrit', 'MCHC', 'Lymphocytes', 'Monocytes', 'Eosinophils', 'Basophils', 'Clinical', 'BUN', 'Potassium', 'Aspartate', 'Total and direct', 'Chemistry1', 'Chloride', 'Aminotransferase', 'bilirubin', 'Bicarbonate', '(AST)/Serum', 'Glutamic-', 'Oxaloacetic', 'Transaminase', '(SGOT)', 'Creatinine', 'Sodium', 'Alanine', 'Total Protein', 'Aminotransferase', '(ALT)/ Serum', 'Glutamic-Pyruvic', 'Transaminase', '(SGPT)', 'Glucose (fasting', 'Calcium', 'Alkaline', 'required for', 'phosphatase', 'screening)', 'Routine', 'Specific gravity', 'Urinalysis', '59']\n\n###\n\n", "completion": "END"}